StemCell Institute

As of March 31, 2026, StemCell Institute carries a market capitalization of 7.71B, placing it among publicly traded companies globally. Its enterprise value stands at 5.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

StemCell Institute's next confirmed earnings release is scheduled for November 10, 2026.

As of March 31, 2026, StemCell Institute has 10.07M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, StemCell Institute maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, StemCell Institute's stock has declined approximately 17.23% over the past 52 weeks. The 50-day moving average sits at 747.46, while the 200-day moving average is 762.22.

As of March 31, 2026, StemCell Institute holds 2.83B in cash and equivalents against 473.81M in total debt, resulting in a net debt position of -2.39B. Total book value stands at 2.68B, with working capital of 781.45M providing operational flexibility.

StemCell Institute's most recent stock split took place on December 29, 2022 with a 1:2 split ratio.